{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-057876","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-05-15T20:41:12+00:00","discovered_at":"2026-05-15T20:44:00.537705+00:00","generated_at":"2026-05-15T21:05:18.045473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius Pharma Q2 2026: $5.6M H1 LYMPHIR revenue, 80% gross margins; raises $36.5M at Citius Oncology","bullets":["Net product revenue $1.7M in Q2 (launch quarter); $5.6M in H1 2026 vs. zero a year ago.","Payer coverage near 100% of commercial lives; 83% of target accounts on formulary or in review.","Citius Oncology secured up to $36.5M debt/equity; Citius Pharma raised $5M direct offering.","Net loss $21.2M in Q2 ($0.95/share) vs. $10.9M a year ago; includes $19.7M CMO cancellation charge.","First LYMPHIR shipment to Europe via Uniphar; positive Phase 1 combo data with pembrolizumab and pre-CAR-T."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-057876","json":"https://secwatch.observer/filing/0001213900-26-057876.json","markdown":"https://secwatch.observer/filing/0001213900-26-057876.md","text":"https://secwatch.observer/filing/0001213900-26-057876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/0001213900-26-057876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/ea0291037-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:05:18.045473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26e89ae8ec90221837e6ad5f97c3fe56ce3375ad","claim":"Citius Pharmaceuticals, Inc. reported fiscal second quarter ended March 31, 2026 results: revenue Net product revenues of $1.7 million for the three months ended March 31, 2026.","evidence_excerpt":"Net product revenues of $1.7 million for the three months ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/0001213900-26-057876-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended March 31, 2026"},{"label":"Revenue","value":"Net product revenues of $1.7 million for the three months ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}